Hypothesis: Microsatellite instability (MSI) correlates with clinicopathologic characteristics and long-term prognosis in patients having gastric carcinoma.
D ESPITE A DECREASING IN-
cidence during the last few decades, gastric carcinoma (GC) remains the fourth most common cancer worldwide and the second leading cause of cancer-related death. 1 The overall mortality has decreased during the same period, although the long-term prognosis remains poor, with 5-year survival rates that rarely exceed 40%. 2 As with most other tumors, GC develops through the accumulation of genetic and epigenetic alterations affecting oncogenes and tumor suppressor genes. It is widely accepted that microsatellite instability (MSI) and chromosome instability are 2 major genomic instability pathways involved in GC pathogenesis. 3 Microsatellite instability has been described as a frequent genetic alteration in colon cancer 4 and in several other cancer types. 5, 6 Although microsatellite alterations have been widely investigated in familial and sporadic colon cancer, 7 limited and inconclusive data are available for stomach cancer.
In the present study, we analyzed a large cohort of patients with GC using a panel of 5 quasimonomorphic mononucleotide repeats (BAT-26, BAT-25, NR-24, NR-21, and NR-27). 8 We assessed clinicopathologic characteristics and long-term prognoses of patients having MSI tumors.
METHODS

STUDY POPULATION
The study analyzed 250 patients with primary GC and operated on at the Division of Surgical Oncology, Tertiary University HospiSee Invited Critique at end of article tal, Policlinico "Le Scotte," University of Siena, Siena, Italy, between January 1, 1990 , and December 31, 2004. All patients underwent resection, including 183 patients with potentially curative (R0) tumors and 35 patients with microscopic (R1) and 32 patients with macroscopic (R2) residual tumors; 20 patients (17 with R1 and R2 residual tumors) had metastatic disease at the time of operation. Clinicopathologic and follow-up data were prospectively collected for the whole cohort. The median follow-up period for surviving patients was 92.1 months (range, 36.3-260.9 months). Informed consent was obtained from all patients. The study was approved by the appropriate local ethics committees.
SURGERY
The objective of surgery was complete resection of the tumor, although gastrectomy was performed even in patients with untreatable disease when required for symptom palliation. Gastric resection was performed based on the extent of tumor in the stomach. Distal subtotal gastrectomy was preferred for tumors located in the lower and middle thirds of the stomach provided that the proximal resection margin remained at least 5 cm from the tumor edge; otherwise, total gastrectomy was performed. 9 Extended (D2) and superextended (D3) lymphadenectomy (in 157 patients [62.8%]) was performed in most R0 resections and has been routinely used since 1995, except for patients deemed unfit for this procedure. 10 None of the patients received preoperative chemotherapy or chemoradiotherapy.
HISTOPATHOLOGIC CLASSIFICATION AND STAGING
Tumor size was calculated by measuring the largest diameter of the neoplasm. The most recent version of the TNM classification by the American Joint Committee on Cancer 11 and the International Union Against Cancer was used for histopathologic staging. Level and number of metastatic lymph nodes were also recorded for each patient. Histologic classification followed the criteria by Lauren 12 ; mixed-type tumors were considered together with diffuse (nonintestinal) type. Lymphatic and vascular invasion was assessed for 176 and 184 patients, respectively.
SAMPLES AND DNA EXTRACTION
Frozen samples of normal mucosa and tumor tissue were available for each patient in our biologic material bank. Tumoral mucosa and corresponding normal mucosa of the stomach were flash-frozen in liquid nitrogen. Tumoral and constitutional DNA were extracted after histopathologic confirmation using a commercially available DNA purification kit (Puregene; Gentra Systems, Inc, Minneapolis, Minnesota) and following the manufacturer's instructions.
PENTAPLEX POLYMERASE CHAIN REACTION AND MICROSATELLITE ANALYSIS
Microsatellite analysis was evaluated using 5 quasimonomorphic mononucleotide repeats, namely, BAT-26, BAT-25, NR-24, NR-21, and NR-27. 8 The 5Ј antisense primer was labeled with a fluorescent dye using FAM for BAT-26 and NR-21, NED for BAT-25 and NR-27, and VIC for NR-24 (ABI PRISM Primer Pairs; Applied Biosystems, Foster City, California).
The 5 mononucleotide repeats were coamplified in one multiplex (pentaplex) polymerase chain reaction (PCR) using the protocol for amplification of microsatellite loci (Multiplex PCR; Qiagen, Studio City, California). The pentaplex PCR was performed on tumoral and matched constitutional DNA of the same patient with GC. The allelic profiles of these 5 mononucleotides were detected on an automated DNA sequencer (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems) according to the manufacturer's protocol (Figure 1 ).
SCORING OF MSI
According to the definition of the National Cancer Institute 5 workshop on MSI for cancer detection and familial predisposition, we considered a tumor as having MSI whenever 2 or more markers showed instability on 5 loci. The clinicopathologic characteristics and survival rates associated with tumors having low instability (one locus involved) are similar to those of stable tumors 5, 13 and were considered together (microsatellite-stable [MSS] phenotype). DNA samples showing an abnormal allelic shift were confirmed by a second PCR and gene scan.
STATISTICAL ANALYSIS
Analyses were performed using commercially available statistical software (SPSS 14.0 for Windows; SPSS Inc, Chicago, Illinois). Statistical associations between clinicopathologic characteristics and MSI status were assessed by 2 test for categorical variables and by t test or analysis of variance for continuous variables. Survival curves were estimated using the KaplanMeier method and were compared using log-rank test. Multivariate analysis was performed using a Cox proportional hazards regression model by considering the following risk factors: sex, age (older vs the median or younger), tumor location (other vs antrum), Lauren 12 histotype (nonintestinal vs intestinal), depth of tumor invasion (pT2, pT3, or pT4 vs pT1), lymph node involvement (pN1, pN2, or pN3 vs pN0), presence of systemic metastasis (M1 vs M0), and R category (R1 or R2 vs R0). Postoperative mortality was assessed, with deaths unrelated to tumor recurrence considered censored observations at the time of death. Because differences in clinicopathologic features and survival rates were observed within the MSI phenotype for tumors with instability at 2 to 4 markers (MSI/Ͻ5) vs tumors with instability at all 5 markers (MSI/5), an analysis was performed The presence of lymphovascular invasion was also evaluated. Both vascular invasion (21.4% vs 53.5%) and lymphatic invasion (33.3% vs 69.3%) were rarely associated with MSI tumors compared with MSS tumors (PϽ.001).
RESULTS
MSI STATUS AND CLINICOPATHOLOGIC FACTORS
MSI STATUS AND SURVIVAL
Kaplan-Meier survival estimates according to MSI phenotype are plotted in Figure 2 . In patients with M0 and R0 disease, 5-year survival was 46% (median, 48.9 months; 95% confidence interval, 31.0-66.8 months) for patients with MSS tumors and 71% (the median was beyond the observation period) for patients with MSI tumors (P=.002).
Multivariate analysis of Cox proportional hazards regression models confirmed MSI as an independent predictor of survival (relative risk vs patients with MSS, 0.62; 95% confidence interval, 0.38-1.00; P=.05). The models controlled for age (P=.74), sex (P=.09), tumor location (P=.70), Lauren 12 histotype (P=.10), depth of tumor invasion (PϽ.001), lymph node involvement (PϽ.001), presence of systemic metastasis (P=.005), and R category (PϽ.001). Table 2 summarizes results of the multivariate analyses using Cox proportional hazards regression models controlling for other risk factors. The MSI/5 phenotype was confirmed to be an independent predictor of long-term survival (relative risk vs patients with the MSS phenotype, 0.32; 95% confidence interval, 0.16-0.63; P=.002).
MSI AT ALL 5 MARKERS
COMMENT
Microsatellite instability is defined as the presence of replication errors resulting in insertions or deletions of bases within nucleotide repeats, known as microsatellite regions. Although a consensus panel for determination of MSI phenotype has been proposed and accepted for colorectal cancer, 5 several markers with differing results have been used for determination of MSI in GC. [14] [15] [16] [17] [18] [19] Based on evaluation using several markers, the MSI phenotype generally characterizes 15% to 25% of patients with GC tumors, more frequently in older women. 3, 18 Most MSI tumors are of intestinal histotype located in the distal part of the stomach, with limited lymph node involvement. Our data regarding MSI phenotype are consistent with other findings reported to date. 3, 18 Several observations of unexpectedly good prognoses in patients with advanced tumors and instability at all 5 markers led us to look at this subset of patients. The case of a 31-year-old woman who had undergone palliative sub- Older age, female sex, antral tumor location, intestinal histotype, less invasion of the serosa, and involvement of fewer lymph nodes significantly correlated with MSI/5 phenotype. The number of involved lymph nodes was particularly low in patients having tumors with instability at all 5 markers. Among 22 patients with MSI/5 pNϩ disease, 21 had fewer than 6 positive lymph nodes, while the 31-year-old patient already mentioned had 8 positive lymph nodes.
Significantly lower rates of lymphovascular invasion were consistently observed for MSI/5 and MSI/Ͻ5 tumors compared with MSS tumors. These data should correlate with less tumor aggression, lower disease stage, and older age in patients with MSI/5 tumors. Some of these characteristics have been reported in MSI tumors, 13 but they seem to be particularly evident in MSI/5 tumors.
The MSI/5 phenotype delineates a subset of tumors with a similar growth pattern but with less propensity to invade serosal layers and spread systemically or via lymph nodes. Considering the locoregional growth of this class of tumors, one could argue for an aggressive surgical approach even in very advanced cases.
Survival analysis confirms high survival rates for patients with MSI/5 tumors (Figures 3 and 4) . Survival of patients with the MSI/5 phenotype was significantly better than that of patients with the MSI/Ͻ5 phenotype, and this difference was confirmed in multivariate analysis. These novel findings identify a particular subset of MSI tumors with less biologic aggression and with a favorable prognosis. Other findings similarly correlate tumor characteristics and differentiation with tumor invasion and genetic changes. 20 In conclusion, our data confirm previous evidence that tumors with MSI demonstrate distinct clinicopathologic features and better prognosis compared with patients having stable tumors. A subset of tumors was observed with instability at 5 quasimonomorphic mononucleotide repeats (BAT-26, BAT-25, NR-24, NR-21, and NR-27) . These tumors have a low predilection to spread systemically or to involve lymph nodes, and they are associated with favorable long-term prognosis even in patients with advanced disease. Further studies among more patients are necessary to confirm our results and to render them reproducible and useful in clinical practice. T he future in staging of cancer is molecular. Molecular markers will ultimately replace pathologic findings in our staging of gastrointestinal cancer. Corso et al from Italy show that genomic MSI in gastric adenocarcinoma is useful in determining the prognosis of patients. DNA from tumor and from adjacent normal tissue was amplified by pentaplex PCR, and DNA fragments were sequenced, which determined the presence of microsatellites.
DNA microsatellites are small (1-3 bp) repetitive DNA sequences, and instability results from the presence of these, which are absent from normal parental DNA. 1 They are the result of mismatch repair gene mutations and have been implicated in hereditary nonpolyposis colorectal cancer 2 ; the present study confirms the utility of MSIs in gastric cancer as well. The authors showed that patients having tumors with all 5 MSI markers did better than those who did not.
Articles describing the use of molecular markers are being published frequently, and the names, functions, and utility of the markers are confusing. The first genetic investigations focused on mutations or deletions in host genomic DNA. A classic study by Shibata et al 3 in 1996 demonstrated that patients with stage II colon cancer who harbored the deleted in colorectal carcinoma (DCC) gene mutation had prognoses similar to those of patients with stage III DCC-positive disease. In the Archives, I recently commented about the utility of cyclooxygenase 2 gene expression as a molecular predictor of the response of colon cancer to chemoradiotherapy. 4 Newer molecular markers focus not on DNA mutations but on molecular changes in genetic expression. Epigenetics includes the study of DNA methylation and of micro RNA inhibition of genetic expression. 5 The former represents inhibition of tumor suppressor gene expression by changes in DNA methylation or enzymatic modification of histone proteins that lead to inhibited DNA repair, replication, and gene expression. The latter comprises inhibition of messenger RNA expression of tumor suppressor genes by small 22-bp endogenous antisense micro RNAs that destroy the message and inhibit expression of tumor suppressor genes. Each molecular marker is complicated to understand and requires extensive study to determine its utility.
Corso et al studied MSI in genomic DNA of gastric cancers and found that patients having tumors with 5 MSI markers have better survival than patients having tumors without MSI markers. This is potentially an important observation because it was true for lymph node-positive gastric cancers with MSI. It is critical to determine whether this is clinically important. One simple test would have been to determine whether survival by stage changes is based on MSI, as assessed by Shibata et al, 3 but no TNM staging was presented in the current article. Similarly, Corso et al could have built on their finding that MSI was more frequent in older women with antral lesions. For example, it could have been determined whether younger men with MSI have survival similar to that of older women without MSI.
Molecular markers of cancer are the wave of the future. We need to determine which marker will be best for each type of cancer, and studies like this are important steps. 
